

REMARKS

Claims 1-45 are pending in the application. Claims 1-45 have been cancelled, and new claims 46-51 have been added to the application by this amendment. Therefore, claims 46-51 are at issue in this continuation application.

This preliminary amendment adds no new matter. The specification has been amended to insert a cross-reference to a related application. Claims 46-51 are fully supported in the specification, for example, at page 4, lines 10-15 and 26-28, at page 40, lines 14-31, and in the originally filed claims, for example, claims 1, 2, 12, and 13.

Pursuant to 37 C.F.R. §1.121, a marked-up version of the changes made to the claims by the present amendment is attached hereto following the signature page of this amendment. The first page of the marked-up version of the changes is captioned "Version With Markings to Show Changes Made."

It is submitted that the claims are in proper form and scope for allowance. Early and favorable action on the merits is respectfully requested.

Should the examiner wish to discuss the foregoing, or any matter of form in an effort to advance this application toward allowance, the examiner is urged to telephone the undersigned at the indicated number.

10077454-001

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By

A handwritten signature in dark ink, appearing to read "James Napoli", is written over a horizontal line.

James J. Napoli
(Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois
February 15, 2002

10077154-021502

Version with Markings to Show Changes Made
Continuation of U.S.S.N. 09/731,591
(27866/36007A), filed December 7, 2000

IN THE SPECIFICATION:

A new cross-reference to related application has been added to the specification at page 1, after the title, as follows:

--CROSS-REFERENCE TO RELATED APPLICATIONS


This application is a continuation of application Serial No. 09/731,591, filed December 7, 2000, now U.S. Patent No. 6,376,489, which claims the benefit of provisional application Serial No. 60/171,023, filed December 23, 1999.--

IN THE CLAIMS:

Cancel claims 1-45.

New claims 46-51 have been added as follows:

46. A method of inhibiting IL-1 β release by monocytes in a mammal comprising administering to said mammal a therapeutically effective amount of a compound having a formula:



wherein R¹ is lower alkyl, bridged alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, a 5- or 6-membered saturated heterocycle, C₁₋₄alkylenearyl, C₁₋₄alkyleneOaryl, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₂₋₄alkylenearylo-aryl, C₁₋₄alkylene bridged alkyl, C₁₋₃alkylenecycloalkyl, substituted or unsubstituted propargyl, substituted or unsubstituted allyl, or halocycloalkyl;

R² is hydrogen, methyl, or halo-substituted methyl;

R³ is selected from the group consisting of C(=O)OR⁷, C(=O)R⁷, C(=NH)NR⁸R⁹, C(=O)NR⁸R⁹, lower alkyl, bridged alkyl, cycloalkyl, haloalkyl, halocycloalkyl, C₁₋₃alkylenecycloalkyl, a 5- or 6-membered saturated heterocycle, aryl, heteroaryl, C₁₋₃alkyleneC(=O)R⁷, C(=O)-C(=O)NR⁸R⁹, C₁₋₄alkyleneOR⁷, C₁₋₃alkylenearyl, SO₂heteroaryl, Het, aralkyl, alkaryl, heteroaralkyl, heteroalkaryl, C₁₋₃alkyleneC(=O)OR⁷, C(=O)C₁₋₃alkyleneC(=O)OR⁷, C₁₋₃alkyleneheteroaryl, C(=O)C(=O)OR⁷, C(=O)C₁₋₃alkyleneC(=O)OR⁷, C(=O)C₁₋₃alkyleneNH(C(=O)OR⁷), C(=O)C₁₋₃alkyleneNH₂, and NHC(=O)OR⁷;

R⁴ is hydrogen, lower alkyl, haloalkyl, cycloalkyl, or aryl;

R⁵ is hydrogen, lower alkyl, alkynyl, haloalkyl, cycloalkyl, or aryl;

R⁶ and R¹², independently, are hydrogen, lower alkyl, aralkyl, SO₂R¹¹, or C(=O)R⁷;

R⁷ is selected from the group consisting of branched or unbranched lower alkyl, heteroaryl, a heterocycle, aralkyl, and aryl, and R⁷ can be optionally substituted with one or more of RO⁸, NR⁸R⁹, or SR⁸;

R⁸ and R⁹, same or different, are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl, heteroaralkyl, hetero-


alkaryl, and aralkyl, or R⁸ and R⁹ can be taken together form a 4-membered to 7-membered ring;

R¹⁰ is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, C(=O)alkyl, C(=O)cycloalkyl, C(=O)aryl, C(=O)-Oalkyl, C(=O)Ocycloalkyl, C(=O)aryl, CH₂OH, CH₂Oalkyl, CHO, CN, NO₂, or SO₂R¹¹;

R¹¹ is alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, or NR⁸R⁹;

salts and solvates thereof.

47. The method of claim 46 wherein the compound has the structure:



48. The method of claim 46 wherein the compound is selected from the group consisting of

Methyl (4S,3R)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-{[benzylamino]methyl}pyrrolidine carboxylate

Methyl (4S,3R)-3-(aminomethyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidinecarboxylate

Methyl (3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-{[methysulfonyl) amino]methyo}pyrrolidinecarboxylate

Methyl (4S,3R)-3-[(acetylamino)methyl]-4-(3-cyclopentyl-oxy-4-methoxyphenyl)-3-methylpyrrolidinecarboxylate

Methyl (4S,3R)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-[(phenylcarbonylamino)methyl]pyrrolidinecarboxylate

Methyl (3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-{[phenylsulfonyl) amino]methyl}pyrrolidinecarboxylate

Bis{[(4S,3R)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-carboxymethylpyrrolidin-3-yl]methyl}amine

1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethylamine

1-{(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl}ethylamine

N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}benzamide

N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}benzamide

N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}acetamide

1007-44-02150
N-{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}acetamide

3-(S)-(1-Acetylaminoethyl)-4-(S)-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidine-1-carboxylic acid methyl ester

{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(phenylsulfonyl)-amine




{1-[(3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(phenylsufonyl)amine

{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(methylsulfonyl)-amine




{1-[(3S,4S)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-3-methyl-1-benzylpyrrolidin-3-yl]ethyl}(methylsulfonyl)-amine, and


Methyl (3S,4S)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methyl-3-[(methylamino)ethylpyrrolidine carboxylate.

49. The method of claim 46 wherein the compound is the group consisting of:




1007154-024502



CN[C@H]1CC[C@@H](C1Cc2ccc(OC3CCCC3)c(O)c2)CN1Cc2ccccc21

- 8 -

said mammal a therapeutically effective amount of a compound having a formula:



wherein R¹ is lower alkyl, bridged alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, a 5- or 6-membered saturated heterocycle, C₁₋₄alkylenearyl, C₁₋₄alkyleneOaryl, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₂₋₄alkylenearyl-Oaryl, C₁₋₄alkylene bridged alkyl, C₁₋₃alkylenecycloalkyl, substituted or unsubstituted propargyl, substituted or unsubstituted allyl, or halocycloalkyl;

R² is hydrogen, methyl, or halo-substituted methyl;

R³ is selected from the group consisting of C(=O)OR⁷, C(=O)R⁷, C(=NH)NR⁸R⁹, C(=O)NR⁸R⁹, lower alkyl, bridged alkyl, cycloalkyl, haloalkyl, halocycloalkyl, C₁₋₃alkylenecycloalkyl, a 5- or 6-membered saturated heterocycle, aryl, heteroaryl, C₁₋₃alkyleneC(=O)R⁷, C(=O)-C(=O)NR⁸R⁹, C₁₋₄alkyleneOR⁷, C₁₋₃alkylenearyl, SO₂heteroaryl, Het, aralkyl, alkaryl, heteroaralkyl, heteroalkaryl, C₁₋₃alkyleneC(=O)OR⁷, C(=O)C₁₋₃alkyleneC(=O)OR⁷, C₁₋₃alkyleneheteroaryl, C(=O)C(=O)OR⁷, C(=O)C₁₋₃alkyleneC(=O)OR⁷, C(=O)C₁₋₃alkyleneNH(C(=O)OR⁷), C(=O)C₁₋₃alkyleneNH₂, and NHC(=O)OR⁷;

R⁴ is hydrogen, lower alkyl, haloalkyl, cycloalkyl, or aryl;

R^5 is hydrogen, lower alkyl, alkynyl, haloalkyl, cycloalkyl, or aryl;

R^6 and R^{12} , independently, are hydrogen, lower alkyl, aralkyl, SO_2R^{11} , or $C(=O)R^7$;

R^7 is selected from the group consisting of branched or unbranched lower alkyl, heteroaryl, a heterocycle, aralkyl, and aryl, and R^7 can be optionally substituted with one or more of RO^8 , NR^8R^9 , or SR^8 ;


R^8 and R^9 , same or different, are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl, heteroaralkyl, heteroalkaryl, and aralkyl, or R^8 and R^9 can be taken together form a 4-membered to 7-membered ring;

R^{10} is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, $C(=O)$ alkyl, $C(=O)$ cycloalkyl, $C(=O)$ aryl, $C(=O)$ oalkyl, $C(=O)$ ocycloalkyl, $C(=O)$ aryl, CH_2OH , CH_2O alkyl, CHO , CN , NO_2 , or SO_2R^{11} ;

R^{11} is alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, or NR^8R^9 ;

salts and solvates thereof.

51. A pharmaceutical composition comprising
(a) a compound having a formula



wherein R¹ is lower alkyl, bridged alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, a 5- or 6-membered saturated heterocycle, C₁₋₄alkylenearyl, C₁₋₄alkyleneOaryl, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₂₋₄alkylenearylOaryl, C₁₋₄alkylene bridged alkyl, C₁₋₃alkylenecycloalkyl, substituted or unsubstituted propargyl, substituted or unsubstituted allyl, or halocycloalkyl;

R² is hydrogen, methyl, or halo-substituted methyl;

R³ is selected from the group consisting of C(=O)OR⁷, C(=O)R⁷, C(=NH)NR⁸R⁹, C(=O)NR⁸R⁹, lower alkyl, bridged alkyl, cycloalkyl, haloalkyl, halocycloalkyl, C₁₋₃alkylenecycloalkyl, a 5- or 6-membered saturated heterocycle, aryl, heteroaryl, C₁₋₃alkyleneC(=O)R⁷, C(=O)-C(=O)NR⁸R⁹, C₁₋₄alkyleneOR⁷, C₁₋₃alkylenearyl, SO₂heteroaryl, Het, aralkyl, alkaryl, heteroaralkyl, heteroalkaryl, C₁₋₃alkyleneC(=O)OR⁷, C(=O)C₁₋₃alkyleneC(=O)OR⁷, C₁₋₃alkyleneheteroaryl, C(=O)C(=O)OR⁷, C(=O)C₁₋₃alkyleneC(=O)OR⁷, C(=O)C₁₋₃alkyleneNH(C(=O)OR⁷), C(=O)C₁₋₃alkyleneNH₂, and NHC(=O)OR⁷;

R⁴ is hydrogen, lower alkyl, haloalkyl, cycloalkyl, or aryl;

R⁵ is hydrogen, lower alkyl, alkynyl, haloalkyl, cycloalkyl, or aryl;

R⁶ and R¹², independently, are hydrogen, lower alkyl, aralkyl, SO₂R¹¹, or C(=O)R⁷;

R⁷ is selected from the group consisting of branched or unbranched lower alkyl, heteroaryl, a heterocycle, aralkyl, and aryl, and R⁷ can be optionally substituted with one or more of RO⁸, NR⁸R⁹, or SR⁸;

R⁸ and R⁹, same or different, are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl, heteroaralkyl, heteroalk-

aryl, and aralkyl, or R^8 and R^9 can be taken together form a 4-membered to 7-membered ring;

R^{10} is hydrogen, alkyl, haloalkyl, cycloalkyl, aryl, $C(=O)$ alkyl, $C(=O)$ cycloalkyl, $C(=O)$ aryl, $C(=O)$ Oalkyl, $C(=O)$ Ocycloalkyl, $C(=O)$ aryl, CH_2OH , CH_2 Oalkyl, CHO , CN , NO_2 , or SO_2R^{11} ;

R^{11} is alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, or NR^8R^9 ,

and salts and solvates thereof;

(b) a pharmaceutically acceptable carrier; and

(c) a second therapeutic agent having utility in the treatment of rheumatoid arthritis.

4007454-02459